



## **Niklas Ehl**

**Assistenzarzt/Assistenzärztin**  
**Kardiologie · Dept. I**

### **Kontakt**

Niklas Ehl  
Rorschacherstrasse 95  
9007 St. Gallen  
Switzerland

T +41 71 494 1124  
T 076-478 2312

[Niklas.Ehl@kssg.ch](mailto:Niklas.Ehl@kssg.ch)

### **Bereiche**

Kardiologie

### **Funktion**

Assistenzarzt/Assistenzärztin

## Publikationen (25)

Brouwers S, Heimgartner R, Laptseva N, Aguzzi A, Ehl N, Fehr T, Hitz F, Jung H, Kälin J, Manz M, Muellhaupt B, Ruschitzka F, Seeger H, Stussi G, Zweier M, Flammer A, Gerber B, Schwotzer R. Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry. *Swiss Med Wkly* 2024; 154:3485.

Dorin P, Kägi G, Ehl N, Vehoff J (2022). Detection rates of atrial fibrillation by prolonged rhythm monitoring with or without preselection by biomarkers in patients with embolic strokes of undetermined source – a single center experience.

Weber L, Ehl N, Buser M, Rigger J, Chronis J, Weilenmann D, Jörg L, Haager P, Rickli H, Maeder M. Hemodynamics Prior to Valve Replacement for Severe Aortic Stenosis and Pulmonary Hypertension during Long-Term Follow-Up. *J Clin Med* 2021; 10

Tschumper M, Ammann P, Jäger-Rhomberg F, Ehl N, Buser M, Brenner R, Seidl S, Rickli H, Weber L, Maeder M. Corrected QT Interval in Severe Aortic Stenosis: Clinical and Hemodynamic Correlates and Prognostic Impact. *Am J Med* 2020

Weber L, Maisano F, Haager P, Buser M, Ehl N, Brenner R, Taramasso M, Ammann P, Rickli H, Maeder M. Hemodynamic profile of patients with severe aortic valve stenosis and atrial fibrillation versus sinus rhythm. *Int J Cardiol* 2020

Maeder M, Maisano F, Ehl N, Buser M, Taramasso M, Jörg L, Haager P, Weilenmann D, Weber L, Rickli H. Invasive Hemodynamic Staging Classification of Cardiac Damage in Patients With Aortic Stenosis Undergoing Valve Replacement. *Can J Cardiol* 2020

Maeder M, Maisano F, Haager P, Brenner R, Gerhard M, Ehl N, Buser M, Ammann P, Weber L, Rickli H. Relationship between B-type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis. *ESC Heart Fail* 2020

Neurauter E, Leschka S, Wildermuth S, Ehl N, Jörg L, Rickli H, Maeder M. Use of coronary computed tomography angiography in clinical practice – single centre experience in Switzerland in light of current recommendations based on pretest probability considerations. *Swiss Med Wkly* 2019; 149:w20010.

Arslani K, Tobler D, Jost C, Ehl N, Rutz T, Bouchardy J, Schwerzmann M, Greutmann M, Zurek M, Roffler N, SACHER Investigators. Patterns of Incidence Rates of Cardiac Complications in Patients With Congenital Heart Disease. *Can J Cardiol* 2018; 34:1624-1630.

Maeder M, Ehl N. When the Right Is Not Doing Right: The Role of Strain Imaging in Pulmonary Arterial Hypertension. *Can J Cardiol* 2018; 34:962-964.

Arendt C, Vogl T, Wildermuth S, Gohmann R, Ehl N, Jörg L, Messerli M, Wichmann J, Tischendorf P, Bauer R. Using coronary CT angiography for guiding invasive coronary angiography: potential role to reduce intraprocedural radiation exposure. *Eur Radiol* 2018; 28:2756-2762.

Messerli M, Rengier F, Desbiolles L, Ehl N, Bauer R, Leschka S, Alkadhi H, Wildermuth S, Nähle C. Impact of Advanced Modeled Iterative Reconstruction on Coronary Artery Calcium Quantification. *Acad Radiol* 2016; 23:1506-1512.

<p>Rigger J, Ehl N, Nägele R, Rickli H, Maeder M. Kounis syndrome revisited: Systemic mastocytosis and severe coronary artery disease. <i>Int J Cardiol</i> 2016; 214:510-1.</p>
<p>Ehl N, Maeder M, Jörg L. Isolated cardiac sarcoidosis: critical role of cardiac MRI for diagnosis and management. <i>Eur Heart J</i> 2015</p>
<p>Rigger J, Ehl N, Nägele R, Rickli H, Maeder M. Giant biventricular thrombi in a patient with heart failure and heparin-induced thrombocytopenia. <i>Int J Cardiol</i> 2015; 182C:377-378.</p>
<p>Ehl N, Zurek M, Rickli H, Maeder M. "Double takotsubo": first description of the sequence of classical followed by inverted type in a young woman. <i>Int J Cardiol</i> 2014; 174:e36-7.</p>
<p>Altmann D, Osswald S, Rickli H, Kühne M, Ammann P, Jörg L, Schär B, Koller M, Ehl N, Mutschelknauss M, Sticherling C. Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction. <i>Swiss Med Wkly</i> 2013; 143:w13869.</p>
<p>Ehl N, Rohner F, Maeder M, Rickli H. Left ventricular apical thrombus many months after pericardial biopsy. <i>Cardiovascular Medicine</i> 2013; 16:132-133.</p>
<p>Arenja N, Osswald S, Hochgruber T, Sou S, Reichlin T, Roost K, Brinkert M, Ehl N, Mueller C, Zellweger M. Prevalence, extent, and independent predictors of silent myocardial infarction. <i>Am J Med</i> 2013; 126:515-22.</p>
<p>Ehl N. Annulus paradoxus. <i>Cardiovascular Medicine</i> 2012; 15:116-118.</p>
<p>Ehl N, Rickli H, Jörg L, Falk V, Weilenmann D, Epp C, Thies S, Geyer R, Sündermann S, Maeder M. Constrictive pericarditis presenting as a large mediastinal mass causing functional tricuspid and pulmonary stenosis. <i>Circulation</i> 2011; 124:e487-91.</p>
<p>Ehl N, Kühne M, Brinkert M, Müller-Brand J, Zellweger M. Diabetes reduces left-ventricular ejection fraction - irrespective of CAD presence and extent. <i>Eur J Endocrinol</i> 2011</p>
<p>Fischer J, Friedli B, Ehl N, Zellweger M. How to evaluate physical fitness without a stress test?. <i>Int J Cardiovasc Imaging</i> 2010</p>
<p>Ehl N, Koller R, Maeder M, Rickli H. Recurrent pericarditis caused by transdiaphragmatic migration of surgical tacks. <i>Eur Heart J</i> 2010; 31:2807.</p>
<p>Ehl N. "Poor man's CRT" - The interesting ECG. <i>Kardiovaskuläre Medizin</i> 2010; Nr. 01/2010:29-30.</p>

## Projekte (3)

**A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)**

*Klinische Forschung - 01.10.2024 - 31.12.2029*

*Geplant*

**Swiss Cardiac Amyloidosis Registry**

*Register - 01.07.2023 - 01.07.2033*

*Laufend*

**TRA 2°P-TIMI 50: Multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie zur Beurteilung der Sicherheit und der Wirksamkeit von SCH 530348 bei Anwendung zusätzlich zur Standardtherapie bei Patienten mit anamnestisch bekannter Atherosklerose: Thrombin-Rezeptor-Antagonist zur Sekundärprophylaxe von atherothrombotischen ischämischen Ereignissen**

*Klinische Forschung - 18.07.2008 - 30.11.2010*

*Abgeschlossen*